Literature DB >> 29074036

Developmental and behavioral aspects of mucopolysaccharidoses with brain manifestations - Neurological signs and symptoms.

Elsa G Shapiro1, Simon A Jones2, Maria L Escolar3.   

Abstract

The mucopolysaccharidoses (MPS) are a group of rare, inherited lysosomal storage disorders, caused by mutations in lysosomal enzymes involved in the degradation of glycosaminoglycans (GAGs). The resulting accumulation of GAGs in the body leads to widespread tissue and organ dysfunction. The spectrum, severity, and progression rate of clinical manifestations varies widely between and within the different MPS types. In addition to somatic signs and symptoms, which vary between the different MPS disorders, patients with MPS I, II, III, and VII present with significant neurological signs and symptoms, including impaired cognitive abilities, difficulties in language and speech, and/or behavioral and sleep problems. To effectively manage and develop therapies that target these neurological manifestations, it is of utmost importance to have a profound knowledge of their natural history and pathophysiology. This review describes the appearance and progression of neurological signs and symptoms in patients with MPS I, II, and III, based on presentations and discussions among an international group of experts during a meeting on the brain in MPS on April 28-30, 2016, and additional literature searches on this subject.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cognition disorders; Lysosomal storage diseases; Mucopolysaccharidoses; Neurobehavioral manifestations

Mesh:

Substances:

Year:  2017        PMID: 29074036     DOI: 10.1016/j.ymgme.2017.08.009

Source DB:  PubMed          Journal:  Mol Genet Metab        ISSN: 1096-7192            Impact factor:   4.797


  18 in total

1.  Clearance of heparan sulfate in the brain prevents neurodegeneration and neurocognitive impairment in MPS II mice.

Authors:  Hideto Morimoto; Sachiho Kida; Eiji Yoden; Masafumi Kinoshita; Noboru Tanaka; Ryuji Yamamoto; Yuri Koshimura; Haruna Takagi; Kenichi Takahashi; Tohru Hirato; Kohtaro Minami; Hiroyuki Sonoda
Journal:  Mol Ther       Date:  2021-01-26       Impact factor: 11.454

Review 2.  Dental-craniofacial manifestation and treatment of rare diseases.

Authors:  En Luo; Hanghang Liu; Qiucheng Zhao; Bing Shi; Qianming Chen
Journal:  Int J Oral Sci       Date:  2019-02-20       Impact factor: 6.344

Review 3.  Novel Enzyme Replacement Therapies for Neuropathic Mucopolysaccharidoses.

Authors:  Yuji Sato; Torayuki Okuyama
Journal:  Int J Mol Sci       Date:  2020-01-08       Impact factor: 5.923

4.  Critical clinical situations in adult patients with Mucopolysaccharidoses (MPS).

Authors:  Karolina M Stepien; Anait K Gevorkyan; Christian J Hendriksz; Tinatin V Lobzhanidze; Jordi Pérez-López; Govind Tol; Mireia Del Toro Riera; Nato D Vashakmadze; Christina Lampe
Journal:  Orphanet J Rare Dis       Date:  2020-05-14       Impact factor: 4.123

Review 5.  Neurobehavioral phenotypes of neuronopathic mucopolysaccharidoses.

Authors:  Rita Barone; Alessandra Pellico; Annarita Pittalà; Serena Gasperini
Journal:  Ital J Pediatr       Date:  2018-11-16       Impact factor: 2.638

6.  Diagnosis of Mucopolysaccharidosis Based on History and Clinical Features: Evidence from the Bajio Region of Mexico.

Authors:  Douglas Colmenares-Bonilla; Christian Colin-Gonzalez; Alejandra Gonzalez-Segoviano; Enrique Esquivel Garcia; Ma Martha Vela-Huerta; Fanny Guadalupe Lopez-Gomez
Journal:  Cureus       Date:  2018-11-20

7.  Craniosynostosis affects the majority of mucopolysaccharidosis patients and can contribute to increased intracranial pressure.

Authors:  Esmee Oussoren; Irene M J Mathijssen; Margreet Wagenmakers; Rob M Verdijk; Hansje H Bredero-Boelhouwer; Marie-Lise C van Veelen-Vincent; Jan C van der Meijden; Johanna M P van den Hout; George J G Ruijter; Ans T van der Ploeg; Mirjam Langeveld
Journal:  J Inherit Metab Dis       Date:  2018-08-06       Impact factor: 4.982

8.  Enzyme replacement therapy in mice lacking arylsulfatase B targets bone-remodeling cells, but not chondrocytes.

Authors:  Gretl Hendrickx; Tatyana Danyukova; Anke Baranowsky; Tim Rolvien; Alexandra Angermann; Michaela Schweizer; Johannes Keller; Jörg Schröder; Catherine Meyer-Schwesinger; Nicole Muschol; Chiara Paganini; Antonio Rossi; Michael Amling; Sandra Pohl; Thorsten Schinke
Journal:  Hum Mol Genet       Date:  2020-03-27       Impact factor: 6.150

9.  Proteomic Analysis of Mucopolysaccharidosis IIIB Mouse Brain.

Authors:  Valeria De Pasquale; Michele Costanzo; Rosa Anna Siciliano; Maria Fiorella Mazzeo; Valeria Pistorio; Laura Bianchi; Emanuela Marchese; Margherita Ruoppolo; Luigi Michele Pavone; Marianna Caterino
Journal:  Biomolecules       Date:  2020-02-26

10.  The nature and impact of neurobehavioral symptoms in neuronopathic Hunter syndrome.

Authors:  J B Eisengart; K E King; E G Shapiro; C B Whitley; J Muenzer
Journal:  Mol Genet Metab Rep       Date:  2019-12-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.